Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 22, Issue -, Pages 79-86Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2015.04.004
Keywords
-
Categories
Funding
- Ministere de l'Enseignement Superieur et de la Recherche
- INSERM
- University of Lyon
- LabEX DEVweCAN [ANR-10-LABX-61]
Ask authors/readers for more resources
Skeletal lesions contribute substantially to morbidity and mortality in patients with cancer. Emerging treatments for metastatic bone disease have arisen from our understanding of the biology of bone metastases. Tumour cells alter the functions of bone-resorbing (osteoclasts) and bone-forming (osteoblasts) cells, promoting skeletal destruction. Drugs that inhibit osteoclast-mediated bone resorption (denosumab, bisphosphonates) are the standard of care for patients with skeletal metastases. In this review, we describe the progress and future directions of novel bone-targeted therapies that not only focus on osteoclasts, but also on osteoblasts and the bone microenvironment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available